FEMYFemasys Inc.
Is Femasys struggling financially?
Yes, by its own account. Femasys told the SEC on 8 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $24.8M
- Source filing
- 10-Q 8 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
0months
If the burn speeds up
Empty by Jun 2026
-
1month
If it eases off
Empty by Jul 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$1.4M
÷
Cash burned over the last 12 months
$31.6M
What Femasys told the SEC
…its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management’s plans will be successful because the availability and amount of such funding are not certain. Accordingly, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do…
Femasys Inc., Form 10-Q, filed 8 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
Other Biotech/Pharma companies that filed the doubt
- VTAK Catheter Precision $3.0M
- ENSC Ensysce Biosciences $7.3M
- PHGE Biomx $3.7M
- VSEE VSee Health Missing
- ALZN Alzamend Neuro $7.5M
- HCWB HCW Biologics $4.0M